Celldex Therapeutics Financial Ratios
NASDAQ: CLDXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Celldex Therapeutics ratio analysis
Celldex Therapeutics earned a net margin of -16748.0% in FY 2025, down from -2248.8% a year earlier. Gross margin was 87.1% compared with a median of 95.8% over the prior 9 years. Return on equity reached -49.1%, meaning Celldex Therapeutics generated -0.49 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Celldex Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 1,161.20 | 245.93 | 279.16 | 0.89 | 0.36 | 0.07 | 0.01 | 0.00 | 28.65 | 52.97 |
| Price / book | 3.40 | 2.31 | 4.48 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 1.54 | 1.35 |
| Gross margin | 87.1% | 97.2% | 95.6% | 95.8% | 97.8% | 97.3% | 97.2% | 92.7% | 94.5% | 76.4% |
| Operating margin | -18,599.8% | -2,778.9% | -2,245.3% | -4,889.0% | -1,531.8% | -854.1% | -1,540.2% | -1,640.1% | -953.7% | -1,958.7% |
| Net margin | -16,748.0% | -2,248.8% | -2,054.8% | -4,765.6% | -1,516.0% | -805.9% | -1,424.0% | -1,585.1% | -730.1% | -1,894.0% |
| Free cash flow margin | -13,829.1% | -2,274.9% | -1,585.2% | -4,478.6% | -1,336.4% | -565.6% | -1,319.5% | -797.3% | -798.2% | -1,706.3% |
| Return on equity (ROE) | -49.1% | -21.1% | -33.0% | -34.4% | -16.8% | -28.6% | -54.1% | -121.9% | -39.4% | -48.4% |
| Return on assets (ROA) | -44.4% | -19.9% | -30.4% | -31.8% | -15.9% | -25.3% | -41.4% | -97.0% | -29.5% | -33.5% |
| Current ratio | 10.49 | 18.91 | 13.87 | 17.07 | 24.86 | 13.93 | 5.73 | 7.86 | 5.22 | 5.55 |
| Revenue growth | -78.0% | 2.0% | 192.0% | -49.3% | -37.3% | 107.6% | -62.5% | -25.2% | 87.8% | 23.8% |